These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 13694297)

  • 1. Clinical evaluation of a new alkylating agent: cytoxan (cyclophosphamide).
    COGGINS PR; RAVDIN RG; EISMAN SH
    Cancer; 1960; 13():1254-60. PubMed ID: 13694297
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative clinical evaluation of two alkylating agents: mannitol mustard and cyclophosphamide (cytoxan).
    PAPAC R; PETRAKIS NL; AMINI F; WOOD DA
    J Am Med Assoc; 1960 Mar; 172():1387-91. PubMed ID: 14430240
    [No Abstract]   [Full Text] [Related]  

  • 3. Cyclophosphamide. A preliminary study of a new alkylating agent.
    FOYE LV; CHAPMAN CG; WILLETT FM; ADAMS WS
    Arch Intern Med; 1960 Sep; 106():365-7. PubMed ID: 13824275
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of malignant disease with an alkylating agent: review of 100 patients treated with "Endoxan".
    REEVE TS
    Med J Aust; 1961 May; 48(1)():686-9. PubMed ID: 13740326
    [No Abstract]   [Full Text] [Related]  

  • 5. A comparative study with three alkylating agents: mechlorethamine, cyclophosphamide, and uracil mustard.
    GOLD GL; SALVIN LG; SHNIDER BI
    Cancer Chemother Rep; 1962 Feb; 16():417-9. PubMed ID: 13899670
    [No Abstract]   [Full Text] [Related]  

  • 6. The treatment of mycosis fungoides with a new agent, cyclophosphamide (Cytoxan).
    ABELE DC; DOBSON RL
    Arch Dermatol; 1960 Nov; 82():725-31. PubMed ID: 13680984
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclophosphamide (Cytoxan) in acute leukemia.
    HOOGSTRATEN B
    Cancer Chemother Rep; 1962 Feb; 16():167-71. PubMed ID: 13908759
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclophosphamide (cytoxan) in acute leukemia, preliminary report.
    HOOGSTRATEN B
    Cancer Chemother Rep; 1960 Jul; 8():116-9. PubMed ID: 14402990
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclophosphamide (Cytoxan) therapy of childhood neuroblastoma. Preliminary report.
    KONTRAS SB; NEWTON WA
    Cancer Chemother Rep; 1961 Jun; 12():39-50. PubMed ID: 13753021
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclophosphamide. A preliminary study of a new alkylating agent.
    FOYE LV; CHAPMAN CG; WILLETT FM; ADAMS WS
    Cancer Chemother Rep; 1960 Feb; 6():39-40. PubMed ID: 13824276
    [No Abstract]   [Full Text] [Related]  

  • 11. The clinical use of epoxypiperazine, a new alkylating agent, in the treatment of lymphomas and other neoplasms.
    MILLER DG; DIAMOND HD; CRAVER LF
    Cancer Res; 1959 Dec; 19():1204-9. PubMed ID: 14422486
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of Hodgkin's disease and the leukemias with cytoxan.
    SAMPEY JR
    Am J Pharm Sci Support Public Health; 1961 Aug; 133():299-304. PubMed ID: 14496659
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical experience with a new alkylating agent AB-132, in the treatment of lymphomas and leukemias.
    STUTZMAN L; RAZIS DV; SOKAL JE; AMBRUS JL; ROSS CA
    Cancer Chemother Rep; 1962 May; 18():31-5. PubMed ID: 13918060
    [No Abstract]   [Full Text] [Related]  

  • 14. The treatment of gynecological cancer with Cytoxan. A preliminary report.
    KELLY TM; FRICK HC
    Bull Sloane Hosp Women Columbia Presbyt Med; 1961; 7():52-4. PubMed ID: 13752404
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of inoperable carcinoma with particular reference to the use of Cytoxan:preliminary report.
    NUGUID TP; BACON HE
    Dis Colon Rectum; 1961; 4():62-6. PubMed ID: 13729880
    [No Abstract]   [Full Text] [Related]  

  • 16. [THE TOTAL BLOOD ALKYLATING AGENT CONCENTRATION IN RATS AFTER ADMINISTRATION OF CYCLOPHOSPHAMIDE AND ACYCLOPHOSPHAMIDE].
    RAUEN HM; KRAMER KP
    Arzneimittelforschung; 1964 Sep; 14():1066-7. PubMed ID: 14344166
    [No Abstract]   [Full Text] [Related]  

  • 17. Enzyme alterable alkylating agents: a new approach to regional chemotherapy by intra-arterial infusion of new short-lived alkylating agents.
    SELIGMAN AM
    Ann Surg; 1962 Sep; 156(3):429-41. PubMed ID: 13910425
    [No Abstract]   [Full Text] [Related]  

  • 18. Effective use of a new alkylating agent in doses lethal to bone marrow with protection by tourniquets of marrow in the extremis.
    GOODMAN LE; SCHILLING A; KRAMER SP; ULFOHN A; MILLER S; KRAVITZ S; GABY SD; BAKAL D; WITTEN B; SELIGMAN AM
    Surg Forum; 1961; 12():130-2. PubMed ID: 13900321
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical observations of 1, 4-bis (2, 3-epoxypropyl)-piperazine: one of a new class of alkylating agents.
    KRAKOFF IH; MILLER DG; KARNOFSKY DA; DIAMOND HD; BURCHENAL JH; CRAVER LF
    Acta Unio Int Contra Cancrum; 1960; 16():867-73. PubMed ID: 14411634
    [No Abstract]   [Full Text] [Related]  

  • 20. Uracil mustard, a new alkylating agent for oral administration in the management of patients with leukemia and lymphoma.
    KENNEDY BJ; THEOLOGIDES A
    N Engl J Med; 1961 Apr; 264():790-3. PubMed ID: 13752496
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.